Upfront Briefing
Novartis just put $575M upfront on the idea that your own cells can brew the drug: global rights to Abogen's mRNA-encoded CD19xCD3 T-cell engager, with up to ~$7.2B in option-heavy milestones. It's a licence, not a takeover, and it's another China-sourced asset in big-pharma hands, so expect the COINS Act crowd to take notes. Elsewhere, Boehringer's survodutide passed Phase 3 and still lost the room, and Lilly showed Foghorn the door after its SMARCA2 bet came up short. EASD wraps today in Milan; the Cell & Gene Meeting on the Mesa opens Monday.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
7,666.5 |
0.2% |
11.8% |
| Nasdaq 100 |
30,501.6 |
0.3% |
21.0% |
| Russell 2000 |
2,806.6 |
0.3% |
11.9% |
| Healthcare (XLV) |
166.2 |
(1.3%) |
6.9% |
| Biotech (XBI) |
154.5 |
(2.0%) |
27.1% |
| Nasdaq Biotech (NBI) |
6,965.6 |
(2.1%) |
22.1% |
| Clinical Trials (BBC) |
45.0 |
(2.8%) |
19.6% |
|
- Biotech lagged a modestly green tape: XBI fell 2.0%, NBI 2.1% and BBC 2.8%, against a 1.3% drop for broad healthcare (XLV) and a 0.2% gain in the S&P 500.
- Bonds set the tone: the 10-year Treasury yield touched about 5.34%, its highest since 2002, before reversing to close near 5.24%, down 6bp, and stocks clawed back from morning lows; the S&P 500 rose 0.2%, the Russell 2000 0.3% and the Nasdaq Composite was flat, with AI infrastructure names leading.
- Market data: U.S. cash close Thursday, 1 October 2026.
The Big 3
|
1
|
Novartis licenses Abogen's in vivo T-cell engager for $575M upfront
|
- Novartis is paying China's Abogen Biosciences $575M upfront for exclusive worldwide rights to ABO2203, a lipid nanoparticle mRNA that has patients' own cells produce a CD19xCD3 T-cell engager, plus exclusive options on further Abogen RNA-platform assets; milestones run to about $7.2B if all options are exercised, plus royalties.
- Why it matters: Novartis is paying a platform price for a thin autoimmune dataset: the published ITP data cover three patients, showing complete B-cell depletion and platelet responses without cytokine release syndrome. The bet is on delivery. An mRNA-encoded engager made in vivo promises subcutaneous, outpatient dosing with no lymphodepletion and lower cost than in vivo CAR-T, and it lands weeks after Novartis paused an autoimmune CAR-T program over three deaths. The B-cell reset thesis survives; the vehicle changes. Read-through runs to recombinant CD19 engagers in autoimmunity and to in vivo CAR-T developers on cost of goods. The headline $7.8B is option-heavy, and a China-sourced licence keeps COINS Act exposure on the file.
- Source: Endpoints
- More: Fierce Biotech; Bloomberg
|
|
2
|
Boehringer's survodutide clears Phase 3, Zealand still slides
|
- Boehringer's SYNCHRONIZE-2 (n=755, obesity or overweight plus type 2 diabetes) met both co-primary endpoints at EASD: 13.1% mean weight loss at week 76 on the high dose versus 3.1% on placebo (efficacy estimand), and 79.3% reaching at least 5% loss versus 32.7%. The NEJM treatment-policy analysis put it at 9.8% versus 3.9%.
- Why it matters: A Phase 3 win that reads as a miss. Boehringer's own efficacy-estimand figure of 13.1% at week 76 sits far below the 23.3% week-48 print Lilly posted for eloraTZP in a similar diabetic population on Wednesday, and the NEJM treatment-policy read is lower still at 9.8%; cross-trial, but the gap is wide. Tolerability is the bigger problem: 26% discontinued for adverse events and 39% vomited, echoing SYNCHRONIZE-1, and a 1.21-point HbA1c drop does not offset it. Zealand fell 11% to DKK241 in Copenhagen; its exposure is up to EUR315M in milestones, with Boehringer solely responsible for development. The remaining case is the liver, where SYNCHRONIZE-1 showed liver-fat reductions of up to 63.1%. Glucagon co-agonists now need a MASH story, not a scale story.
- Source: Fierce Biotech
- More: NEJM; BioSpace
|
| 3 | Foghorn cuts 40% as Lilly exits SMARCA2 pact |
- Lilly and Foghorn are ending their 2021 collaboration after Phase 1 dose-escalation data for FHD-909 (LY4050784), a selective SMARCA2 (BRM) inhibitor in SMARCA4-mutant NSCLC, fell short; a SMARCA2 degrader and an undisclosed oncology program go with it. Foghorn is cutting 40% of staff, leaving 65 employees.
- Why it matters: A clean negative on SMARCA2/4 synthetic lethality. Foghorn says FHD-909 hit SMARCA2 selectively at exposures above its preclinical targets, which moves the failure from chemistry to biology and leaves little room to blame the molecule. That travels: Prelude already paused its SMARCA2 degraders after an underwhelming Phase 1, and SMARCA4 mutations sit in about 10% of NSCLC. Lilly's 2021 entry cost $300M upfront plus an $80M equity investment. Foghorn had $167.6M at end-June and guides runway into the second half of 2029, but the pipeline is now preclinical, led by an EP300 degrader it hopes to take into Phase 1 next year. Until then the equity trades on cash and platform credibility.
- Source: Fierce Biotech
- More: BioSpace; GlobeNewswire
|
Everything Else that broke
- FDA approved Bristol Myers Squibb's Camzyos for symptomatic obstructive HCM in pediatric patients weighing at least 30 kg, the first drug cleared to improve functional capacity and symptoms in children with the condition. — FDA
- J&J posted two-year Icotyde (icotrokinra) data in difficult-to-treat plaque psoriasis, including 60% complete scalp clearance and 89% complete genital clearance. — PR
- Taiho reported a Phase 3 win for an oral chemotherapy combination in blood disorders that can progress to AML. — Fierce Pharma
- STAT reports the Trump administration watered down a Medicare drug-pricing model as the MAHA Summit took on a more corporate cast. — STAT
Deal Flow
|
BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
-
Novartis licensed Abogen's CD19xCD3 mRNA T-cell engager ABO2203 for $575M upfront and up to about $7.2B in option-heavy milestones (see The Big 3). — Fierce Biotech
- Samfara completed its acquisition of Chr. Olesen Synthesis, a Danish controlled-substance API manufacturer. — PR
VC / Private Financings
- TriGemX raised $94M for a migraine therapy after Kallyope's rebrand; syndicate included The Column Group, TCGX, Viking Global Investors and others. — BioCentury
- Skopos Bio, a Peter MacCallum Cancer Centre radiopharmaceutical spinout, launched with an A$12M (~US$8.3M) seed round co-led by Tenmile, Tin Alley Ventures and Yosemite; its lead prostate cancer program is moving toward first-in-human trials. — DDW
IPOs / Follow-Ons
- No notable IPOs / follow-ons in the last 24 hours. — BioBucks
Academic Corner - Urine cell-free RNA profiling showed high sensitivity for bladder cancer detection across more than 600 patients and controls. — Nature Medicine
|
